Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

Abstract Background Cisplatin is a first-line drug for the treatment of human non-small cell lung cancer (NSCLC); however, the majority of patients will develop drug resistance after treatment. In order to overcome cisplatin resistance, it is important to understand the mechanisms underlying the res...

Full description

Bibliographic Details
Main Authors: Wenjing Wang, Mengyue Zhao, Lijuan Cui, Yong Ren, Jingyuan Zhang, Junli Chen, Lina Jia, Jiayu Zhang, Jingyu Yang, Guoliang Chen, Charles R. Ashby, Chunfu Wu, Zhe-Sheng Chen, Lihui Wang
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Molecular Cancer
Subjects:
Cisplatin resistance
Lung cancer
HtrA1
HDAC
RXR
Online Access:http://link.springer.com/article/10.1186/s12943-020-01256-9

Internet

http://link.springer.com/article/10.1186/s12943-020-01256-9

Similar Items